GlassScriptPhysician profile
David B Oneal
NPI 1235134735
$2,236.24
in general payments reported to CMS, 2019-2025
32 companies · $1,787 in 2025
The $1,787 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $172 · 2020: $63.14 · 2021: $11.70 · 2022: $12.04 · 2023: $65.56 · 2024: $125 · 2025: $1,787.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,961 · Education: $16.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,961.07 |
| Education | $16.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $271.11 | 2021-2025 | |
| Ucb, INC. | $257.54 | 2025 | Briviact, Rystiggo |
| Otsuka America Pharmaceutical, INC. | $167.64 | 2025 | Rexulti |
| Acadia Pharmaceuticals INC | $158.38 | 2025 | Nuplazid |
| Biogen, INC. | $143.35 | 2025 | Leqembi |
| Sunovion Pharmaceuticals INC. | $126.51 | 2019 | |
| Eisai INC. | $125.84 | 2025 | |
| Pfizer INC. | $91.48 | 2024-2025 | |
| Neurocrine Biosciences, INC. | $91.46 | 2025 | |
| Neurelis, INC. | $75.75 | 2025 | Valtoco |
| Janssen Biotech, INC. | $73.36 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $71.20 | 2025 | Hyqvia |
| Axsome Therapeutics, INC. | $58.79 | 2025 | Symbravo |
| Lilly USA, LLC | $58.53 | 2025 | Kisunla |
| Genzyme Corporation | $53.14 | 2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atland Pharmaceuticals, LLC | $49.37 | 2025 | Tolmetin Sodium, Orphenadrine Citrate, Aspirin and Caffeine |
| Lundbeck LLC | $39.19 | 2025 | Vyepti |
| Mdd US Operations, LLC | $36.86 | 2025 | |
| Allergan, INC. | $33.38 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $29.76 | 2020 | |
| Alexion Pharmaceuticals, INC. | $29.64 | 2025 | Ultomiris |
| Genentech USA, INC. | $24.94 | 2025 | Ocrevus Zunovo |
| Argenx US, INC. | $22.00 | 2025 | Vyvgart Hytrulo |
| Kedrion Biopharma, INC. | $18.67 | 2025 | Gammaked, Kedrab, Koate |
| Amneal Pharmaceuticals LLC | $18.65 | 2025 | Crexont |
| Teva Pharmaceuticals USA, INC. | $18.49 | 2025 | Austedo Xr |
| Livanova USA, INC. | $17.29 | 2019 | |
| Catalyst Pharmaceuticals, INC. | $16.72 | 2024 | |
| Alnylam Pharmaceuticals INC. | $15.00 | 2025 | Amvuttra |
| Supernus Pharmaceuticals, INC. | $14.88 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $14.43 | 2025 | |
| Novartis Pharmaceuticals Corporation | $12.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Oneal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.